Legalized cannabis, whether for recreational or medicinal purposes, is at the center of one of the nation’s most transformative industries. Since the passing of California’s Compassionate Use Act of 1996, which made the state the first in the country to legalize medical marijuana, states across the country have been reevaluating the federal government’s decision to outlaw cannabis. In 2012, Colorado and Washington state took another step toward the legalization of cannabis with Amendment 64 and Initiative 502, respectively. With these two measures, the first states in the Union approved the use of marijuana for recreational purposes. Since that vote, the national marijuana industry has been in a period of rapid growth. Following last Tuesday’s election, a majority of 26 states, as well as the District of Columbia, now have laws legalizing marijuana in some form.

Despite the national prevalence of legalized weed, banking remains a major point of contention for the burgeoning marijuana industry. This is because financial institutions are caught between state laws allowing for the sale of marijuana and federal laws that ban it. While the U.S. Treasury and Justice departments previously stated that they won’t pursue institutions that keep a close eye on marijuana-related clients and report any suspected wrongdoing, the need to closely monitor clients in the sector has led many large banks to steer clear of the industry. The result has been the emergence of an all-cash industry, leaving dispensaries and other marijuana-focused businesses unable to accept credit or debit cards from customers.

Operating without electronic payment options isn’t just inconvenient; it can be outright dangerous. A report by the Wall Street Journal (http://dtn.fm/8yo8T) published earlier this year notes that marijuana business owners have taken to “refurbishing retired armored bank trucks to transport money and hiring heavily armed security guards.” With more than half the country having now legalized marijuana in some form, many in the industry feel that the tides could be turning, and Singlepoint, Inc. (OTC: SING), through its SingleSeed subsidiary, is positioning itself to capitalize on this shift.

“For far too long, dispensaries and other marijuana businesses have struggled to maintain a secure and convenient financial position due to legislation that prohibits them from having bank accounts,” Greg Lambrecht, chief executive officer of Singlepoint, stated in a news release issued this morning. “On Tuesday night, seven states loudly voiced their support for legalization. The issue is now too big to ignore, and we expect that Washington will have to hammer out details to create a ‘bankable environment’ for institutions ready to take part in history.”

Earlier this month, Singlepoint announced plans to awaken SingleSeed from a quiet period as politicians on both sides of the aisle continue to push for solutions to the marijuana banking conundrum. With the market for both medical and recreational marijuana projected to grow from about $7 billion this year to roughly $22 billion by 2020, according to ArcView Research, SingleSeed will look to capitalize on a first mover advantage in the cannabis merchant processing business by developing a marketing program specifically designed for cannabis accounts. Before this can be implemented, though, legislators will need to address the banking issue, as Lambrecht alluded to in this morning’s update.

“When that time comes, SingleSeed will already be ahead of the game with its cannabis merchant payment processing services and technologies,” he concluded.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

Before the opening bell, National Waste Management Holdings, Inc. (OTC: NWMH) announced its financial results for the three months ended September 30, 2016. Notably, the company achieved year-over-year revenue growth of 269 percent, recording $1.7 million in total revenue for the quarter. National Waste recorded similar growth for the first nine months of 2016, with total revenue of $4.8 million, which marked an increase of 262 percent from the comparable period of 2015.

This financial growth is largely attributable to the company’s aggressive acquisition strategy, highlighted through the 2015 acquisitions of Waste Recovery Enterprises and Gateway Rolloff Services. National Waste leveraged this strategy once again in June of this year, when it acquired Sivart Services, a roll-off and compactor business located in Worchester, New York, in an effort to expand its geographic footprint in the northeast while supporting additional revenue growth.

“We are pleased to report our third-quarter 2016 results, marking three consecutive quarters of triple-digit quarterly revenue growth. Our third-quarter performance largely reflects the effectiveness of our acquisition strategy and, in correlation, our growing customer base,” Louis Paveglio, chief executive officer of National Waste, stated in this morning’s news release. “Moving forward, we expect to see continued improvements in profitability as a result of our acquisitions of WRE and Gateway in 2015, supported by our acquisition of Sivart Services earlier this year and our rapidly expanding presence in the northeast.”

In addition to its strong financial performance, National Waste made efforts to strengthen its position in the solid waste management industry during the third quarter by expanding its management team. On August 18, 2016, the company appointed Dali Kranzthor to the position of chief financial officer. Kranzthor added considerable financial experience to the National Waste team, having previously served in leadership roles with numerous privately-held and publicly-held firms located throughout Florida. Most recently, he served as the director of audit and assurance and valuation services at a boutique accounting firm in St. Petersburg, where he worked with both large private businesses and high wealth individuals.

“During the third quarter of 2016 we continued to execute on our business model and build our team and footprint through effective management and acquisitions,” Kranzthor added in this morning’s news release. “When I joined National Waste in the fall of this year, I walked into a flurry of progression and look forward to providing my expertise for continued growth for the remainder of 2016 and beyond.”

Moving forward, National Waste could look to continue its revenue growth through the completion of additional accretive acquisitions. In a news release earlier this year, Paveglio stated that National Waste had already identified a number of potential acquisition targets that are consistent with its business strategy. The momentum provided by these and other ongoing initiatives is expected to spur additional revenue growth as National Waste continues to expand its solid waste solutions in order to meet growing demand.

For more information, visit the company’s website at www.nationalwastemgmt.com

Let us hear your thoughts: National Waste Management Holdings, Inc. Message Board

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, reflected on Tuesday’s polling results, particularly as they relate to the legalization of recreational and medicinal marijuana in states across the country. In total, four states – including California, Maine, Massachusetts and Nevada – voted to legalize marijuana for recreational use, bringing the nationwide total to eight states, in addition to the District of Columbia. Additionally, four states voted to legalize or expand the availability of medicinal marijuana. With this vote, a nationwide majority of 28 states and Washington, D.C. have now legalized cannabis for medicinal purposes.

“As more and more states pass not only recreational but medical marijuana, there’s going to be more and more pressure on the legislators and also the administration to allow them to have bank accounts which, in turn, will allow us to put in our credit card merchant processing and let customers pay with their credit cards for cannabis,” Lambrecht stated in the interview.

This result is big news for Singlepoint, as the company recently awakened its SingleSeed subsidiary from a quiet period in order to actively engage the roughly $6 billion industry. Though banks and credit unions across the country have been extremely reluctant to open accounts for dispensaries and other companies operating in the burgeoning cannabis industry, SingleSeed already has experience servicing this market. Lambrecht alluded to this experience in the interview.

“We already spent the time and money of understanding this business and we’re in hundreds of accounts allowing people to use their debit cards, and the banks shut it down. As this gets back opened up, we’re really ready to go,” he continued. “In fact, we’re going to be putting on our SingleSeed.com website a sign-up now for dispensaries to kind of get in line and put their name and information down. That way, when it opens up, we can call them immediately and get them started.”

There’s little doubt that change is coming in the domestic cannabis industry, even as the drug remains illegal at the federal level. To date, about 266 depository institutions nationwide have begun serving marijuana-related businesses, and the U.S. Treasury Department’s 2014 decision to green light banks to offer their services to the industry, as long as any suspicious activity is reported to federal authorities, will likely play a role in continued growth in the financial sector moving forward. This hypothesis played a role in Arcview Research’s projection that the combined domestic medicinal and recreational marijuana markets will climb to a valuation of $22 billion by 2020.

With Singlepoint’s renewed interest in the sector, Lambrecht finished off the MoneyTV interview by announcing plans to attend the 5th Annual Marijuana Business Conference & Expo® in Las Vegas, which begins on November 15. According to Lambrecht, he intends to discuss possible acquisitions within the space, as well as to present the benefits of SingleSeed to existing dispensaries.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

The era of the super bug is upon us, and Achaogen, Inc. (NASDAQ: AKAO) has joined the fray against them. For close to one hundred years, antibiotics have lowered the prevalence and severity of infectious diseases. Increasingly, though, it is becoming apparent that the bacterial world is fighting back. Infections of the urinary tract (UTI) and others such as acne, bronchitis and streptococcal pharyngitis (strep throat) are becoming more resistant to the antibiotics that are most commonly prescribed to treat them.

And this threat is compounded by the rise of the super bug, strains of bacteria that have already evolved defenses against a range of antibiotics. However, Achaogen is close to launching a new line of attack against these pathogens. Two phase III trials for its lead product candidate are currently in progress, and top-line results from both are expected in the first quarter of 2017.

Up until the 1930s, we were at the mercy of bacterial infections. Indeed, it was only about half a century before, in 1876, when German physician Robert Koch, in identifying the causes of anthrax, cholera and tuberculosis, showed that bacteria caused disease. In 1928, Dr. Alexander Fleming made the astounding discovery that the penicillium mold inhibited the growth of bacteria, and the penicillin extracted there from set a new paradigm for twentieth-century medical science. A PBS story (http://dtn.fm/Yl2DQ) gives some idea of its success:

“In the war, penicillin proved its mettle. Throughout history, the major killer in wars had been infection rather than battle injuries. In World War I, the death rate from bacterial pneumonia was 18 percent; in World War II, it fell, to less than 1 percent.”

Dr. Fleming was awarded the Nobel Prize in 1945, and, in his acceptance speech, he issued a prescient warning that the improper use of penicillin might eventually make it ineffective. If the drug could ‘be bought by anyone in the shops, then there is the danger that the ignorant man may easily under dose himself and by exposing his microbes to non-lethal quantities of the drug make them resistant.’ Unfortunately, this prophesy has come true. Not only for penicillin, but for a wide range of other antibiotics, effectiveness today is markedly down from previous decades.

These dangers are exacerbated by a range of super bugs that are multi-drug resistant (MDR) and include carbapenem-resistant Enterobacteriaceae (CRE). Generally, healthy people in their normal environments do not contract CRE infections. Such maladies arise in hospitals, nursing homes, and other health care settings. It is for such malaises that Plazomicin is being developed. The drug will be used to treat serious bacterial infections due to MDR Enterobacteriaceae, including CRE.

It is currently being evaluated in two phase III clinical trials. For the first, designated EPIC (Evaluating Plazomicin in cUTI), Achaogen completed enrollment ahead of schedule in September with 609 patients. Top-line results are expected in the first quarter of 2017. The EPIC study is intended to serve as a single pivotal trial supporting a New Drug Application (NDA) for Plazomicin in the United States in the second half of 2017.

The second CARE (Combating Antibiotic Resistant Enterobacteriaceae) Phase III trial is for patients with serious bacterial infections due to CRE. Due to rapid completion of enrollment of the EPIC trial, Achaogen closed enrollment in the CARE trial with 69 patients and expects to announce top-line data from this trial early in the first quarter of 2017 as well. Results from CARE will be submitted with the NDA.

The FDA has granted Qualified Infectious Disease Product (QIDP) designation to Plazomicin, and development and regulatory review of its use to treat serious and life-threatening CRE infections has been given Fast Track status. The plazomicin program is partially funded by up to $103.8 million from the Biomedical Advanced Research and Development Authority (BARDA).

A report (http://dtn.fm/GKWi3) from Aegis Capital Corp. has set a target PPS of $10.00 for Achaogen. The company’s stock, under the symbol AKAO, is currently trading on the NASDAQ at under $5.00.

For more information, please visit www.achaogen.com

The alternative lodging rental market is maturing quickly, being one of the fastest growing verticals in the travel industry over the last few years. Already believed to be worth more than $100 billion worldwide, the sector continues to expand rapidly as more and more vacation rentals companies are joining the game alongside the now-famous HomeAway, Booking.com and Airbnb. Monaker Group, Inc. (OTCQB: MKGI), a technology-driven travel group that offers comprehensive tourism solutions and personalized tours, already maintains an important presence in the alternative lodging market, with a portfolio of more than one million rental units available.

The vacation rental market began expanding more quickly in the Internet era, starting with booking site VRBO, which was set up back in 1996 by a Colorado couple. The business was acquired by HomeAway in 2006 and became the dominant vacation rental listings hub. In 2015, HomeAway was purchased by Expedia (NASDAQ: EXPE) for $3.9 billion, a move that consolidated Expedia’s position as one of the largest online travel agents (OTA) operating at the moment. According to Expedia CEO Dara Khosrowshahi, the alternative lodging rental segment has become a major part of Expedia’s business, now having more than one million bookable listings available. The number continues to grow at a fast rate of over 20 percent, Khosrowshahi said.

Another major OTA, Priceline (NASDAQ: PCLN) occupies a good portion of the vacation rentals market through Booking.com listings. Booking.com now has about half a million instantly bookable vacation rental properties, which is almost 40 percent higher than in 2015. The approximately 1 million total properties listed on the website make for approximately 23.7 million bookable rooms, 7.3 million of which are in apartments, homes or villas, while the rest are in traditional hotels.

Capitalizing on a global trend of tourists looking for more personalized experiences wherever they travel, the vacation rental market is expected to grow significantly over the next few years, likely reaching $170 billion by 2019. Most of this growth is owed to Europe and the U.S., where the alternative lodging model is highly popular, according to a Research and Markets report (http://dtn.fm/mUT1g). Approximately 24 percent of travelers have opted for alternative lodging during the past two years, while roughly 47 percent are interested in staying at a vacation rental unit in the near future. In the U.S. in 2015, one in three tourists stayed in a private accommodation, which marks a significant change from 2011, when only one in ten Americans used alternative lodging.

With a portfolio of more than 1.1 million alternative lodging rental units available under its NextTrip Resorts platform, and currently in the process of adding more than 200,000 timeshare and resort units by the end of the year, Monaker Group is poised to establish a growing presence in the global vacation rentals market. The group owns several travel-related businesses, but its flagship is undoubtedly NextTrip.com, which allows tourists to plan their trips to the smallest details by offering them access to a wealth of alternative lodging options such as vacation home rentals, resort residences and unused timeshare inventory, all alongside a wide range of hotels, tours, rental cars, airlines, concierge services and more. The platform, launched in February 2016, has grown exponentially, being the first and only real-time booking engine that combines various booking options to meet tourists’ every need.

To further support the vacation rental market, Monaker Group this summer launched a Premium Service for alternative lodging owners, aimed at helping them compete against major travel industry suppliers, including hotels, car rental companies and airlines. The service offers various tools and features that will give homeowners real-time booking capabilities, the ability to update property pricing daily so as to better reflect the market conditions, and other benefits.

For more information, visit www.MonakerGroup.com

Let us hear your thoughts: Monaker Group, Inc. Message Board

Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on developing and delivering biased ligands to discover the next generation of GPCR targeted medicine. The company is focused on three product candidates:

• Oliceridine, for moderate to severe acute pain;
• TRV734, an oral use medicine for people in moderate, severe acute, and chronic pain;
• and TRV250, for those suffering from migraines.

On November 7, 2016, Aegis Capital Corp. (http://dtn.fm/bB9sC) initiated coverage on Trevena, Inc., offering the company a ‘Buy’ rating with a target price of $14. This rating was released soon after the company reported its third quarter 2016 financial results alongside a corporate update. In the press release, CEO Maxine Gowen reported important progress for the quarter ending September 30, 2016.

According to Trevena’s third quarter report, top-line data from its APOLLO-1 and APOLLO-2 phase III efficacy trials of Oliceridine is on track for release in the first quarter of 2017, and the patient enrollment remains on track in the ETHENA multi-procedure safety study of Oliceridine to support an NDA filing in 2H 2017. Trevena, Inc. also announced that its TRV250 program is on track for IND submission this year.

The company has reported continued engagement at pain medicine conferences, and has hosted an investor webcast featuring presentations on acute pain management by leading clinicians.

Out of the seven analysts who have covered Trevena this year, six rated the company at ‘Buy’ and one at ‘Hold’. In the first weeks of November, Trevena has reported a stock price increase of roughly 50 percent to $5.75 per share as of November 11, an increase of $1.94 per share from its November 3 PPS.

For more information, visit the company’s website at www.trevena.com

Last month, Celldex Therapeutics, Inc. (NASDAQ: CLDX), a company in the business of developing targeted therapeutics for those suffering from devastating diseases for which current treatments are inadequate, found positive results from its phase II study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory. The study showed that patients experienced a confirmed response, with 52% of patients experiencing tumor shrinkage. In addition, by close of market on November 8, 2016, Celldex stock was up significantly as investors reacted to the company’s third quarter earnings report, which surpassed estimates for revenue and EPS. CLDX’s stock rose by nearly 15% to close at $3.78 on 9.01 million shares, more than four times the company’s average.

Aside from its recent growth, Celldex announced the acquisition of Kolltan Pharmaceuticals, Inc. on November 1. Kolltan is a privately owned clinical-stage company that develops new antibody-based drugs and is worth $62.5 million in stock. “Celldex believes Kolltan’s clinical candidates and preclinical platform are highly compatible with the Company’s scientific approach and can be developed independently and in combination with Celldex’s existing product candidates,” according to a statement shared on the Scibility Media website (http://dtn.fm/aD3xZ).

On November 7, Aegis Capital Corp. (http://dtn.fm/bXxJ5) initiated coverage on Celldex Therapeutics, Inc., giving the company a ‘Buy’ rating and a target price of $10. In addition, as of November 8, 2016, ClosingBell Active Analyst Ratings (http://dtn.fm/0W6w6) gave CLDX an average stock rating of 3.6 on a one to five scale, with five denoting ‘Buy’ and one indicating ‘Sell’. The numbers above are predicted to allow Celldex Therapeutics, Inc. to fund its operations through 2018.

For more information, visit the company’s website at www.celldex.com

Major Depressive Disorder (MDD) afflicts about 15 million Americans and is the leading cause of disability in the U.S. for those aged 15-44, according to the National Institute of Mental Health. Although experiencing the blues is part of the human condition, MDD is more than just the sadness that accompanies misfortune. MDD is a chronic feeling of enervation, loss of interest in activities, pessimism and hopelessness. At one time regarded as caused by supernatural forces, today, modern medical science generally attributes depression to chemical imbalances in the brain. However, with its small-molecule benzylpiperazine-aminopyridine drug NSI-189, Neuralstem, Inc. (NASDAQ: CUR) has evolved a new approach to lifting the blues.

NSI-189 was developed as a result of the research, undertaken by Neuralstem, into neural stem cell lines from the human hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. In a process referred to as neurogenesis, NSI-189 was shown to stimulate the generation of new neurons in vitro and in animal models. In phase Ib human clinical trials for MDD, NSI-189 demonstrated ‘clinically meaningful’ improvement across all depressive and cognitive measures.

This approach based on neurogenesis is a novel one. Current medications for depression generally attempt to modulate levels of different chemicals (neurotransmitters) in the brain. The most common type of such treatments is thought to be selective serotonin reuptake inhibitors (SSRIs).

In addition to the brain chemistry factors that cause depression, modern scholarship has uncovered a link between depression and the physiology of the brain. Those who suffer from chronic depression display reduced hippocampal volume. The healthy hippocampus, however, is a rich source of neural stem cells, from which new neurons are generated, making vital new connections throughout life. Neuralstem believes that stimulating the generation of new neurons in the hippocampus could potentially address the pathology of the depression itself.

Phase Ia trials, testing NSI-189 for use against MDD, kicked off in February 2011 and ended in October 2011. Healthy volunteers, unafflicted by depression, were tested with escalating single administration doses of NSI-189. Later, a similar trial was conducted for depression patients. In phase Ib, which commenced in June 2012 and ended in the fourth quarter of 2013, the safety of escalating doses of NSI-189 for 28 daily administrations in 24 patients suffering from MDD was tested.

At present, enrollment for a phase II trial has commenced. The trial, which is already 50 percent enrolled, is expected to yield top line results in the second half of 2017.

NSI-189 has had a colorful history. This feature in Bethesda magazine (http://dtn.fm/aRw8k) claims that NSI-189 stems from efforts by the Defense Advanced Research Projects Agency (DARPA), most famously home to the genesis of the internet, to cultivate ‘a “super soldier” who could stay awake and alert for a week at a time’. The contract was later cancelled and Neuralstem turned its attention to developing a remedy for the cell damage that can occur in the sleep-deprived hippocampus.

Neuralstem has the resources to expedite the clinical trial process. Through a recent agreement with the Tianjin Pharmaceutical Holding Group, the company has secured $20 million for completion of the phase II trial. This supplements the $11.1 million in cash on the balance sheet at the end of 2Q16.

In a report by Aegis Capital Corp. (http://dtn.fm/cZW0X), Neuralstem stock has been given a price target of $2.25. The share price on November 7 was $0.23. It seems that NSI-189 is lifting more than the blues.

For more information, visit www.neuralstem.com

Before the opening bell, Medical Transcription Billing, Corp. (NASDAQ: MTBC; MTBCP) announced its financial and operational results for the third quarter of 2016, including a review of the October acquisition of MediGain, LLC and subsidiary Millennium Practice Management, LLC, which was the company’s largest acquisition to date. Notably, MTBC’s revenues for the three-month period were $5.3 million, up from $5.2 million in the previous quarter. The company also achieved its fourth consecutive quarter of positive adjusted EBITDA, reporting $130,000 for the third quarter and $209,000 year-to-date.

“We are pleased to announce another quarter of quarter-over-quarter revenue growth,” Mahmud Haq, chairman and chief executive officer of MTBC, stated in this morning’s news release. “Even though we continue to report a GAAP net loss, which is largely a result of non-cash amortization and depreciation expense, we are proud to report four consecutive quarters of positive adjusted EBITDA.”

Perhaps MTBC’s most significant achievement in the third quarter, the acquisition of Texas-based medical billing company MediGain, LLC, including substantially all of its assets and its subsidiary, positioned the company to build on its recent financial momentum moving forward. In total, the accounts in good standing acquired through this transaction have annual revenues in excess of $10 million. At a purchase price of just $7 million, the MediGain acquisition is expected to be accretive to MTBC shareholders in 2017, as incremental profits are expected to greatly exceed cost of capital. The acquisition also expanded MTBC’s global workforce, adding experienced team members in North America, as well as talented, cost-effective workforces in Asia.

“The successful closing of this transaction has positioned MTBC to experience exponential growth through access to new, untapped markets,” Haq continued. “In turn, we expect to expand our client base and deliver significant revenue growth in 2017.”

MTBC also reiterated plans for an upcoming offering of additional shares of its non-convertible Series A Preferred Stock in this morning’s update. The company is currently preparing to file a registration statement to sell 400,000 additional shares of its 11 percent Series A Cumulative Redeemable Perpetual Non-Convertible Preferred Stock at a price of $25 per share. If all of the shares are sold, the offering will generate roughly $9 million, of which $5 million will be used for the remaining payments related to the MediGain acquisition. This offering is not dilutive to shareholders and is expected to play a key role in positioning MTBC for forward growth.

Following this morning’s release, MTBC management hosted a conference call to discuss the results. An audio webcast of the call will be made available to the investment community on the company’s investor relations website at http://ir.mtbc.com.

For more information, visit www.mtbc.com, and see the company’s fact sheet at http://ir.mtbc.com/events.cfm.

It is no secret that the United States is going through some serious changes when it comes to marijuana. In the recent election, several states approved the legalization of marijuana for recreational purposes, with other states voting to approve medical marijuana initiatives. With Donald Trump winning the presidential election, it brings forward the question: how will this new presidency affect the marijuana industry in the U.S.?

Prior to the election, Alicia Wallace from the Cannabist (http://dtn.fm/8zKZ3) was able to share the four leading presidential candidates’ views on marijuana, including Trump’s. While the leading third-party candidates supported the legalization of marijuana, the Democratic and Republican party candidates did not seem as convinced, although neither took a particularly strong public stance on the matter.

While Trump showed strong views in favor of the legalization of all drugs back in 1990, they have been modified. In his more recent interview, Trump backed the use of medical marijuana, though he believes recreational use should be up to the states.

Although there has been talk of New Jersey Governor Chris Christie, who is not in favor of the legalization of marijuana, being a contender for the post of Attorney General, the marijuana industry does not yet seem to be worried. During an interview with television reporter Brandon Rittiman, Trump stood by his view of it being ‘up to the states’.

As a result, Singlepoint, Inc. (OTC: SING) subsidiary SingleSeed, a cannabis focused company established a few years ago to offer payment processing services to dispensaries, aims to capitalize on its current status within the marijuana industry while expanding to additional states.

By the end of this year, the size of the legal marijuana industry in the U.S. is projected to grow to $7.1 billion, according to a report by New Frontier and ArcView Market Research (http://dtn.fm/vE0s3). This represents a 26% jump from 2015, which is said to be largely due to expected adult recreational sales. States which have legalized marijuana are seeing a growth in what people are calling “green” taxes. Colorado is a prime example of how the legalization of marijuana can contribute to the financial status of each state, with revenue in “green” taxes of $70 million between 2014 and 2015.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board